Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-carnitine adjunct therapy for septic shock with acute kidney injury
2016-001977-34Phase 3Active
- Sponsor
- CHU Nîmes
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of levocarnitine in septic shock (2 arms), sponsored by CHU Nîmes. Primary endpoint: 28-day mortality. Started Sep 2017; status: active.
02
Drugs
levocarnitine
03
Conditions
septic shock
Beyond the preview
Go deeper on 2016-001977-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001977-34.